A Trial of Favipiravir and Hydroxychloroquine combination in Adults Hospitalized with moderate and severe Covid-19: A structured summary of a study protocol for a randomised controlled trial
Letter
[키워드] 1:1
accompany
adjusted
Admission
Affair
age
analyst
antibiotic
antiviral therapy
Arrhythmias
blinded
Breastfeeding
breathing ambient air
Care
Child-Pugh score
Chronic kidney disease
city
classical
clinical
clinical effectiveness
Clinical improvement
clinical sample
clinical symptom
clinically
Coma
Combination
Comorbidity
comparator
Compliance
conducted
control arm
control group
Controlled clinical trial
COVID-19
current
Dammam
data entry
death
deficiency
defined
diagnosed with COVID-19
dialysis
discharge
discharged
disease
disease onset
dissemination
drug
ECMO
effective sample size
Efficacy
Efficacy and safety
eight
element
enrolled
Enrollment
evaluate
Evidence
experimental arm
extracorporeal membrane oxygenation
Faisal
Favipiravir
female
G6PD
Glucose-6-phosphate
hereditary xanthinuria
HIV
hospital
Hospital admission
Hospitalized
Hydroxychloroquine
Hyperuricemia
ICU admission
Imam
immunosuppressive
in vitro
include
information
Intervention
intravenous fluid
invasive ventilation
investigator
Jeddah
King
less
limit
Liver damage
Major
malignancy
medication
moderate
multicenter
Multicenter trial
Myocardial infarction
noninvasive
nonpregnant
number
objective
ongoing trial
outcome
oxygen saturation
Palliative care
participant
Patient
PCR
pregnant
primary endpoint
prior diagnosis
prognostic
prolonged QT interval
protocol
QT interval
randomised
randomised controlled trial
randomization
Randomized
receiving
recruitment
reference
risk
Sample size
SARS-CoV-2
Saudi Arabia
selected
seven-category ordinal scale
Standard
Stratification
study drug
Study protocol
subject
supplemental oxygen
Supportive treatment
Symptom
System
tablets
the patient
therapeutic agent
therapy
transferred
Treatment
Trial
ULN
Urinary tract
use of hydroxychloroquine
vasopressor support
ventricular
viral infection
Web
website
with COVID-19
xanthine
[DOI] 10.1186/s13063-020-04825-x PMC 바로가기 [Article Type] Letter
[DOI] 10.1186/s13063-020-04825-x PMC 바로가기 [Article Type] Letter